About the ECHO® Program
Empowering the Care Team: Practical Strategies for Implementing BCMA Therapies in Relapsed Refractory Multiple Myeloma
Through interactive cases and expert-led discussions, our ECHO® sessions and Community of Practice calls help community oncology teams:
- Characterize the safety and efficacy of BCMA-directed bsAbs for the treatment of MM
- Appropriately incorporate BCMA-directed bsAbs into cases of patients with MM that are representative of clinical practice
- Establish and follow workflows and lines of communication for monitoring and managing BCMA bsAb treatment-related adverse events
- Summarize the importance and benefits of CoPs to providing coordinated, multidisciplinary, and interprofessional care for patients with MM receiving BCMA-directed bsAbs
ECHO Sessions highlight the importance of monitoring known risks like cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, emphasizing careful patient selection and adherence to safety protocols to optimize outcomes.
Community of Practice calls discuss barriers or challenges to implementing what was discussed during the ECHO sessions, address any additional questions, and help develop solutions to overcome barriers.
You will be taken to the Boston University Center for Continuing Education’s registration website.
7:00 PM EST
Learning Objectives
- Explain the mechanism of action of BCMA bsAbs
- Characterize the safety and efficacy of BCMA-directed bsAbs for the treatment of MM
- Appropriately incorporate BCMA-directed bsAbs into cases of patients with MM that are representative of clinical practice
Faculty:
7:00 PM EST
Learning Objectives
- Describe the diagnosis, risk factors, prevention and management of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS)
- Recognize infectious complications associated with BCMA-directed bispecific antibodies and implement strategies for their prevention.
- Establish and follow workflows and lines of communication for monitoring and managing BCMA bsAb treatment-related adverse events (TRAEs)
Faculty:
7:00 PM EST
Learning Objectives
- Define the role of academic centers and community practices in providing BCMA targeting BsABs
- Summarize the importance and benefits of CoPs to providing coordinated, multidisciplinary, and interprofessional care for patients with MM receiving BCMA-directed bsAbs
- Appropriately incorporate BCMA-directed bsAbs into cases of patients with MM that are representative of clinical practice
Faculty:
7:00 PM EST
Learning Objectives
- Recognize the physical, emotional, and social quality of life (QoL) of patients treated with BCMA targeting BsABs
- Evaluate tools and strategies for assessing patient-reported outcomes and quality of life
- Develop personalized support plans that integrate multidisciplinary resources
Faculty:
7:00 PM EST
Learning Objectives
- Identify and categorize barriers to accessing BCMA-directed therapies for patients with multiple myeloma
- Discuss the impact of these barriers on health outcomes in various contexts
- Propose evidence-informed strategies and policy solutions to mitigate these barriers
Faculty:
7:00 PM EST
Learning Objective
- Appropriately incorporate BCMA-directed bsAbs into cases of patients with MM that are representative of clinical practice
Faculty: